Amerigen Pharmaceuticals, Inc.

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Generic Drugs
See more in Biomedtracker

Latest on Amerigen Pharmaceuticals, Inc.

Generics Bulletin

FTC Argues Forest Side Deals In Bystolic Pay-For-Delay Case May Be Unjustified Payments

 
• By Brenda Sandburg

The US Federal Trade Commission contends that a district court got it wrong in finding that Forest Laboratories, Inc. ’s side deals with generic manufacturers did not constitute unjustifiable payment

Pink Sheet

FTC Argues Forest Side Deals In Bystolic Pay-For-Delay Case May Be Unjustified Payments

 
• By Brenda Sandburg

The US Federal Trade Commission contends that a district court got it wrong in finding that Forest Laboratories, Inc. ’s side deals with generic manufacturers did not constitute unjustifiable payment

Generics Bulletin

ANI Grabs 23 US Products From Amerigen

 
• By Aidan Fry

ANI Pharmaceuticals is paying Amerigen Pharmaceuticals up to $77.5m for a US portfolio of 23 approved and pipeline generics. The acquired portfolio includes 10 marketed products, three approved pro

Scrip

Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway

 
• By Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Pfizer Licenses Asset With P